Logo image
Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy
Journal article   Open access   Peer reviewed

Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy

Clayton T Marcinak, William F Parker, Alexander A Parikh, Jashodeep Datta, Shishir K Maithel, David A Kooby, Mark E Burkard, Hong Jin Kim, Michael T LeCompte, Majid Afshar, …
Journal of surgical oncology, Vol.128(2), pp.280-288
08/2023
DOI: 10.1002/jso.27287
PMCID: PMC10330210
PMID: 37073788
url
https://doi.org/10.1002/jso.27287View
Published (Version of record) Open Access

Abstract

Outcomes for pancreatic adenocarcinoma (PDAC) remain difficult to prognosticate. Multiple models attempt to predict survival following the resection of PDAC, but their utility in the neoadjuvant population is unknown. We aimed to assess their accuracy among patients that received neoadjuvant chemotherapy (NAC). We performed a multi-institutional retrospective analysis of patients who received NAC and underwent resection of PDAC. Two prognostic systems were evaluated: the Memorial Sloan Kettering Cancer Center Pancreatic Adenocarcinoma Nomogram (MSKCCPAN) and the American Joint Committee on Cancer (AJCC) staging system. Discrimination between predicted and actual disease-specific survival was assessed using the Uno C-statistic and Kaplan-Meier method. Calibration of the MSKCCPAN was assessed using the Brier score. A total of 448 patients were included. There were 232 (51.8%) females, and the mean age was 64.1 years (±9.5). Most had AJCC Stage I or II disease (77.7%). For the MSKCCPAN, the Uno C-statistic at 12-, 24-, and 36-month time points was 0.62, 0.63, and 0.62, respectively. The AJCC system demonstrated similarly mediocre discrimination. The Brier score for the MSKCCPAN was 0.15 at 12 months, 0.26 at 24 months, and 0.30 at 36 months, demonstrating modest calibration. Current survival prediction models and staging systems for patients with PDAC undergoing resection after NAC have limited accuracy.
Adenocarcinoma - surgery Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - surgery Female Humans Male Middle Aged Neoadjuvant Therapy Neoplasm Staging Nomograms Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - surgery Prognosis Retrospective Studies

Details

Metrics

Logo image